Drug Profile


Alternative Names: F 11105; L 0066

Latest Information Update: 21 Jul 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pierre Fabre
  • Developer Pierre Fabre; University Hospital Ghent
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Immunomodulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 21 Jul 2000 L 0066 is now called Ataquimast
  • 10 May 1999 Discontinued-I for Asthma in Belgium (PO)
  • 10 May 1999 Discontinued-I for Asthma in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top